Categories: HealthcareNews

Avantor® to Report Fourth Quarter and Full Year 2024 Earnings on Friday, February 7, 2025

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

RADNOR, Pa., Jan. 10, 2025 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 7, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time.

To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor’s website, ir.avantorsciences.com. A replay of the webcast will be available for 30 days.

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908.329.7281
Allison.Hosak@avantorsciences.com 

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-to-report-fourth-quarter-and-full-year-2024-earnings-on-friday-february-7-2025-302347601.html

SOURCE Avantor and Financial News

Staff

Recent Posts

Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025

Ontada researchers to present 14 data presentations at ISPOR 2025 including a podium presentation on…

1 hour ago

HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

Board expansion reflects Company’s commitment to leadership and innovation in remote cardiac monitoring SANTA CLARA,…

1 hour ago

IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment

DiaSafe™, IR-MED's second product, is being developed to provide safe, real-time optical readings of biomarkers…

1 hour ago

NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025

Financial results to be released before market open; Conference call to be conducted at 9:00…

1 hour ago

Cannabix Technologies Receives NHTSA Approval for BreathLogix Workplace Series Alcohol Breathalyzer

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of…

1 hour ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Company continues to expand global IP coverage and claims to major markets, now extending to…

1 hour ago